Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -6762.77% as of the fiscal period ended Tuesday, March 31, 2026.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-6762.77%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$5.20M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
Market Cap
$5.23M
EBITDA Margin
-2579.35%
TTM Avg
-2579.35%
3Y Avg
-2089.74%
5Y Avg
-2089.74%
Market Cap
$5.24M
EBITDA Margin
-123.71%
TTM Avg
-161.92%
3Y Avg
-255.04%
5Y Avg
-225.97%
Market Cap
$5.17M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.27M
EBITDA Margin
-271.50%
TTM Avg
-294.22%
3Y Avg
-453.19%
5Y Avg
-366.18%
Market Cap
$5.08M
EBITDA Margin
-4837.99%
TTM Avg
-4449.42%
3Y Avg
-4104.15%
5Y Avg
-4023.55%
Market Cap
$4.79M
EBITDA Margin
-1670.57%
TTM Avg
-1446.66%
3Y Avg
-2067.25%
5Y Avg
-1679.39%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.21M | -6762.77% | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.20M | -8.85% | 9.13% | 18.32% | 18.32% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
| Pulmatrix, Inc. (PULM)vs › | $5.24M | -123.71% | -161.92% | -255.04% | -225.97% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.17M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | -271.50% | -294.22% | -453.19% | -366.18% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.08M | -4837.99% | -4449.42% | -4104.15% | -4023.55% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.79M | -1670.57% | -1446.66% | -2067.25% | -1679.39% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.72M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-6762.8%
Operating Margin
0.0%
Net Margin
-612568.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -6762.77% |
